Reduced elimination of IgG antibodies by engineering the variable region.
Fc engineering to increase the binding affinity of IgG antibodies to FcRn has been reported to reduce the elimination of IgG antibodies. Herein, we present a novel non-FcRn-dependent approach to reduce the elimination of IgG antibodies. Pharmacokinetic studies conducted in normal mice of various humanized IgG4 antibodies, which had identical constant regions but different variable region sequences, revealed that an antibody with a lower isoelectric point (pI) has a longer half-life. These antibodies exhibited comparable binding affinity to FcRn, and with the antibodies with lower pIs, a longer half-life was also observed in beta2-microglobulin knockout mice, suggesting that differences in the pharmacokinetics were due to a non-FcRn-dependent mechanism. On the basis of our findings, we attempted to engineer the pharmacokinetic properties of a humanized anti-IL6 receptor IgG1 antibody. Selected substitutions in the variable region, without substitution in the Fc region, lowered the pI but did not reduce the biological activity and showed a significant reduction in the clearance of the antibody in cynomolgus monkey. These results suggest that lowering the pI by engineering the variable region could reduce the elimination of IgG antibodies and could provide an alternative to Fc engineering of IgG antibodies.
Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd, Shizuoka 412-8513, Japan. igawatmy@chugai-pharm.co.jp
T
T
Igawa
H
H
Tsunoda
T
T
Tachibana
A
A
Maeda
F
F
Mimoto
C
C
Moriyama
M
M
Nanami
Y
Y
Sekimori
Y
Y
Nabuchi
Y
Y
Aso
K
K
Hattori
D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000493:pharmacokinetics; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D005818:Genetic Engineering / Q000379:methods*; D006207:Half-Life; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000235:genetics* / Q000378:metabolism; D007135:Immunoglobulin Variable Region / Q000235:genetics*; D007526:Isoelectric Point; D051379:Mice; D015202:Protein Engineering / Q000379:methods*; D011961:Receptors, Fc / Q000378:metabolism
D000911:Antibodies, Monoclonal; D015395:Histocompatibility Antigens Class I; D007074:Immunoglobulin G; D007135:Immunoglobulin Variable Region; D011961:Receptors, Fc; C100688:Fc receptor, neonatal